ACTIVE

Confo Therapeutics

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

-17,4 M €

-53.6% YoY

Revenue

176,7 k €

-86.1% YoY

Equity

33,3 M €

-34.3% YoY

Workforce

59,0 ETP

+13.5% YoY

What does Confo Therapeutics do?

Confo Therapeutics is a Public limited company incorporated in 2015. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 59,0 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0632.474.939

Incorporation

11/06/2015

Legal form

Public limited company

Registered office

Technologiepark-Zwijnaarde 30
9052 Gent · FlandreSee on map

Contributed capital

76 768 745,00 €

Latest accounts

31/12/2025

Average workforce

59,0 ETP

Activities (NACE)

72101Research and experimental development on natural sciences and engineering· main 72109Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology 72190Other research and experimental development on natural sciences and engineering

Joint committees (1)

Signals

Solid equityLow riskGood liquidityPositive cashflowHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 7 financial years

	2025		2024		2023		2022		2021		2020		2018
Income statement
Revenue	176,7 k €	-86.1%	1,3 M €	-97.3%	46,6 M €	+9210%	500 k €		–		–		–
EBITDA	-949,2 k €	+92.1%	-12 M €	-137%	32,1 M €	+316%	-14,9 M €	-55.4%	-9,6 M €	-13.0%	-8,5 M €	-168%	-3,2 M €
Operating result	-19,5 M €	-53.8%	-12,7 M €	-141%	31,3 M €	+299%	-15,7 M €	-51.8%	-10,4 M €	-11.3%	-9,3 M €	-149%	-3,7 M €
Net result	-17,4 M €	-53.6%	-11,3 M €	-136%	31,1 M €	+300%	-15,6 M €	-58.2%	-9,9 M €	-11.1%	-8,9 M €	-154%	-3,5 M €
Balance sheet
Equity	33,3 M €	-34.3%	50,6 M €	+115%	23,6 M €	+412%	-7,6 M €	-194%	8 M €	-23.0%	10,4 M €	+34.7%	7,7 M €
Total assets	37,8 M €	-31.1%	54,8 M €	+24.6%	44 M €	+225%	13,5 M €	-22.5%	17,5 M €	+24.5%	14 M €	+46.0%	9,6 M €
Cash	6,2 M €	+21.3%	5,1 M €	-26.8%	6,9 M €	+96.9%	3,5 M €	-67.2%	10,7 M €	+47.3%	7,3 M €	+14.0%	6,4 M €
Debts	3,4 M €	+28.9%	2,7 M €	-84.6%	17,3 M €	-3.6%	17,9 M €	+111%	8,5 M €	+643%	1,1 M €	+33.4%	858,5 k €
Other
Workforce	59,0 ETP	+13.5%	52,0 ETP	+13.3%	45,9 ETP	-21.0%	58,1 ETP	+4.9%	55,4 ETP	+10.6%	50,1 ETP	+135%	21,3 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 50 M€ and 100 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 7 active · 39 ended

Active mandates

Jeroen VANGINDERTAEL

Director · since 18 juillet 2024 · until 18 juillet 2030

Active

Dieter WEINAND

Director · since 25 août 2023 · until 05 juin 2027

Active

Caroline GODDEERIS

Director · since 30 avril 2022 · until 18 juillet 2030

Active

WELLINGTON PARTNERS LIFE SCIENCES V GMBH & CO. KG

Director · since 15 juin 2021 · until 18 juillet 2030

Represented by Varun GUPTA

Active

Robert SCOTT

Director · since 04 juin 2020 · until 05 juin 2027

Active

Edward VAN WEZEL

Director · since 07 février 2019 · until 18 juillet 2030

Active

Cedric VERVERKEN

Managing director · since 08 septembre 2016 · until 18 juillet 2030

Active

Ended mandates

Participatiemaatschappij Vlaanderen

Director · since 13 novembre 2023 · until 07 juin 2029 · 0455.777.660

Represented by Bart DE TAEYE

Ended

Dieter WEINAND

Director · since 25 août 2023 · until 05 juin 2025

Ended

Caroline GODDEERIS

Director · since 30 avril 2022 · until 30 avril 2028

Ended

Caroline GODDEERIS

Director · since 30 avril 2022 · until 07 juin 2029

Ended

At this address

Other companies at this address

Company	CBE no.
DEVGEN● Active	0461.432.562
Eastman Chemical Technology● Active	0671.793.393
Syngenta Seeds● Active	0404.599.569

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	08/06/2026	12/06/2025	17/07/2024	05/06/2023	04/07/2022	23/06/2021
General meeting	04/06/2026	05/06/2025	28/06/2024	01/06/2023	30/06/2022	03/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

11 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	04/06/2026	08/06/2026	Dutch	PDF
Full model	31/12/2024	05/06/2025	12/06/2025	Dutch	PDF
Full model	31/12/2023	28/06/2024	17/07/2024	Dutch	PDF
Full model	31/12/2022	01/06/2023	05/06/2023	Dutch	PDF
Abridged model	31/12/2021	30/06/2022	04/07/2022	Dutch	PDF
Abridged model	31/12/2020	03/06/2021	23/06/2021	Dutch	PDF
Abridged modelCorrection	31/12/2019	04/06/2020	02/07/2020	Dutch	PDF
Abridged model	31/12/2019	04/06/2020	15/06/2020	Dutch	PDF
Abridged model	31/12/2018	06/06/2019	13/06/2019	Dutch	PDF
Abridged model	31/12/2017	07/06/2018	19/06/2018	Dutch	PDF
Abridged model	31/12/2016	01/06/2017	08/06/2017	Dutch	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 50 M€ and 100 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 7 active · 39 ended

Active mandates

Jeroen VANGINDERTAEL

Director · since 18 juillet 2024 · until 18 juillet 2030

Active

Dieter WEINAND

Director · since 25 août 2023 · until 05 juin 2027

Active

Caroline GODDEERIS

Director · since 30 avril 2022 · until 18 juillet 2030

Active

WELLINGTON PARTNERS LIFE SCIENCES V GMBH & CO. KG

Director · since 15 juin 2021 · until 18 juillet 2030

Represented by Varun GUPTA

Active

Robert SCOTT

Director · since 04 juin 2020 · until 05 juin 2027

Active

Edward VAN WEZEL

Director · since 07 février 2019 · until 18 juillet 2030

Active

Cedric VERVERKEN

Managing director · since 08 septembre 2016 · until 18 juillet 2030

Active

Ended mandates

Participatiemaatschappij Vlaanderen

Director · since 13 novembre 2023 · until 07 juin 2029 · 0455.777.660

Represented by Bart DE TAEYE

Ended

Dieter WEINAND

Director · since 25 août 2023 · until 05 juin 2025

Ended

Caroline GODDEERIS

Director · since 30 avril 2022 · until 30 avril 2028

Ended

Caroline GODDEERIS

Director · since 30 avril 2022 · until 07 juin 2029

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates04/03/2026
ONTSLAGEN - BENOEMINGEN
PDF
Other26/01/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Other26/11/2025
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates28/07/2025
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - ONTSLAGEN - BENOEMINGEN
PDF
Other16/01/2025
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates31/07/2024
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
PDF
Other31/07/2024
DIVERSEN
PDF
Mandates11/06/2024
ONTSLAGEN - BENOEMINGEN
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

11/02/2026
nominationVarun Gupta — Investeerder Bestuurder
11/02/2026
nominationJeroen Vangindertael — Investeerder Bestuurder
11/02/2026
nominationEdward van Wezel — Investeerder Bestuurder
11/02/2026
nominationCaroline Goddeeris — Investeerder Bestuurder
11/02/2026
nominationRobert Scott — Onafhankelijke Bestuurder
11/02/2026
nominationDieter Weinand — Onafhankelijke Bestuurder
11/02/2026
nominationCedric Ververken — Bestuurder
01/01/2026
nominationStephen Dowd — Chief Business Officer (CBO)
01/01/2026
nominationFrank Landolt — Chief Counsel Intellectual Property
01/01/2026
nominationPaolo Vicini — Chief Development Officer (CDO)
01/01/2026
nominationChristel Menet — Chief Scientific Officer (CSO)
2025
Annual accounts 2025-17,4 M €↓
05/06/2025
reconductionDieter Weinand — Onafhankelijke Bestuurder
05/06/2025
reconductionRobert Scott — Onafhankelijke Bestuurder
2024
Annual accounts 2024-11,3 M €↓
18/07/2024
nominationCedric Ververken — Chief Executive Officer (CEO)
18/07/2024
augmentation_capital
18/07/2024
augmentation_capital
08/03/2024
nominationVarun Gupta — vaste vertegenwoordiger voor de uitoefening van haar bestuursmandaat
08/03/2024
unknownBart De Taeye — Investeerder Bestuurder
08/03/2024
unknownEdward van Wezel — Investeerder Bestuurder
08/03/2024
unknownCaroline Goddeeris — Investeerder Bestuurder
08/03/2024
unknownRobert Scott — Onafhankelijke Bestuurder
08/03/2024
unknownDieter Weinand — Onafhankelijke Bestuurder
08/03/2024
unknownCedric Ververken — bestuurder
2023
Annual accounts 202331,1 M €↑
15/11/2023
nominationBart De Taeye — vaste vertegenwoordiger
25/08/2023
nominationDieter Weinand — Onafhankelijke Bestuurder
25/08/2023
nominationParticipatieMaatschappij Vlaanderen NV — Investeerder A Bestuurder
25/08/2023
nominationWellington Partners Life Sciences V GmbH & Co. KG — Investeerder B Bestuurder
25/08/2023
nominationEdward van Wezel — Investeerder B Bestuurder
25/08/2023
nominationCaroline Goddeeris — Investeerder B Bestuurder
25/08/2023
nominationRobert Scott — Onafhankelijke Bestuurder
25/08/2023
nominationCedric Ververken — bestuurder
2022
Annual accounts 2022-15,6 M €↓
30/06/2022
reconductionJohn Berriman — Onafhankelijk Bestuurder
30/06/2022
reconductionRobert Scott — Onafhankelijk Bestuurder
30/06/2022
reconductionBDO Bedrijfsrevisoren — commissaris
31/05/2022
nominationCaroline Goddeeris — bestuurder
2021
Annual accounts 2021-9,9 M €↓
01/10/2021
nominationJos Peeters — vaste vertegenwoordiger
2020
Annual accounts 2020-8,9 M €↓
2018
Annual accounts 2018-3,5 M €
11/06/2015
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

Confo Therapeutics

Overview

What does Confo Therapeutics do?

Trend over 7 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline